BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 38579072)

  • 1.
    El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Bajjou T; Sekhsokh Y; Benmokhtar S; Jafari M; Baba W; Oukabli M; El Annaz H; Abi R; Tagajdid MR; El Kochri S; Lahlou IA; Ameziane El Hassani R; Ennibi K
    Cancer Control; 2024; 31():10732748241262179. PubMed ID: 38875469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.
    Lee SM; Oh H
    Sci Rep; 2024 May; 14(1):11432. PubMed ID: 38763942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep neural network for the prediction of KRAS, NRAS, and BRAF genotypes in left-sided colorectal cancer based on histopathologic images.
    Li X; Chi X; Huang P; Liang Q; Liu J
    Comput Med Imaging Graph; 2024 Jul; 115():102384. PubMed ID: 38759471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Incidence of common gene mutations in early-onset colorectal cancer and the association with cancer survival: a meta-analysis].
    Zhang RQ; Li SH; Hu TJ; Xu LY; Zhu YS; Li X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 May; 27(5):495-506. PubMed ID: 38778689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue Elasticity as a Diagnostic Marker of Molecular Mutations in Morphologically Heterogeneous Colorectal Cancer.
    Plekhanov AA; Kozlov DS; Shepeleva AA; Kiseleva EB; Shimolina LE; Druzhkova IN; Plekhanova MA; Karabut MM; Gubarkova EV; Gavrina AI; Krylov DP; Sovetsky AA; Gamayunov SV; Kuznetsova DS; Zaitsev VY; Sirotkina MA; Gladkova ND
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.
    Dorard C; Madry C; Buhard O; Toifl S; Didusch S; Ratovomanana T; Letourneur Q; Dolznig H; Garnett MJ; Duval A; Baccarini M
    Oncogene; 2023 May; 42(20):1649-1660. PubMed ID: 37020037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the Interplay of KRAS, NRAS, BRAF, and Micro-Satellite Instability in Non-Metastatic Colon Cancer: A Systematic Review.
    Orlandi E; Giuffrida M; Trubini S; Luzietti E; Ambroggi M; Anselmi E; Capelli P; Romboli A
    Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786299
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Benmokhtar S; Laraqui A; Hilali F; Bajjou T; El Zaitouni S; Jafari M; Baba W; Elannaz H; Lahlou IA; Hafsa C; Oukabli M; Mahfoud T; Tanz R; Ichou M; Ennibi K; Dakka N; Sekhsokh Y
    Clin Med Insights Oncol; 2024; 18():11795549241255651. PubMed ID: 38798959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients - a single-institution experience utilising circulating tumour DNA.
    Zarkavelis G; Amylidi AL; Torounidou N; Yerolatsite M; Keravasili A; Keramisanou V; Mauri D
    Contemp Oncol (Pozn); 2024; 28(1):45-50. PubMed ID: 38800532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
    Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
    Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
    Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
    Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
    Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
    Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Martianov AS; Mitiushkina NV; Ershova AN; Martynenko DE; Bubnov MG; Amankwah P; Yanus GA; Aleksakhina SN; Tiurin VI; Venina AR; Anuskina AA; Gorgul YA; Shestakova AD; Maidin MA; Belyaev AM; Baboshkina LS; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902296
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.